Skip to main content

Table 5 Time to recurrence (TTR)a and cancer-specific survival (CSS)b of patients with intestinal-type adenocarcinomas

From: EGFR gene amplification is relatively common and associates with outcome in intestinal adenocarcinoma of the stomach, gastro-oesophageal junction and distal oesophagus

  Univariate survival analysis for TTR Multivariate survival analysis for TTR Univariate survival analysis for CSS Multivariate survival analysis for CSS
  Number of patients TTR, median (months) P value, log-rank testc P value, Cox testd HR 95 % CI P value, Cox testb HR 95 % CI Number of patients CSS, median (months) P value, log-rank testa P value, Cox testd HR 95 % CI P value, Cox testb HR 95 % CI
Age (continuous variable) 198    NS       212    0.048 1.02 1.00–1.04 NS   
Patient gender
 Female (reference) 71 56.6 NS NS       78 45.6 NS NS      
 Male 127 38.2         134 44.6        
Site of primary tumour       
 Distal oesophagus/GOJ/cardia (reference) 75 28.5 NS NS       77 34.3 NS       
 Corpus/antrum/pylorus 123 53.6      NS    135 47.1   NS      
Histological differentiation grade
 Grade I (reference) 30 NA NS        30 NA NS       
 Grade II 92 33.8   0.043 1.95 1.02–3.74 NS    98 33.8   0.020 2.22 1.13–4.36 NS   
 Grade III 76 53.2   NS    NS    84 44.6   0.029 2.15 1.08–4.27 NS   
Postoperative T
 pT1 (reference) 37 67.3 <0.0001        37 NA <0.0001       
 pT2 31 NA   NS       31 NA   NS      
 pT3 75 56.6   NS       82 57.3   NS      
 pT4 55 20.5   0.002 2.59 1.44–4.67     59 25.7   0.001 2.94 1.58–5.47    
Postoperative stage
 I (reference) 58 NA 0.005        58 NA <0.0001       
 II 80 38.2   NS    NS    80 57.3   NS    NS   
 III 60 22.6   0.001 2.33 1.38–3.92 0.014 2.05 1.16–3.63 60 29.0   0.002 2.36 1.37–4.08 0.023 1.99 1.10–3.61
 IV NA          14 6.90   <0.0001 14.2 6.86–29.3 <0.0001 11.4 5.34–24.4
EGFR amplification
 Yes 28 21.8 0.026 0.028 1.73 1.06–2.83 NS    30 29.0 0.033 0.035 1.67 1.04–2.69 NS   
 No (reference) 170 56.6         182 57.3        
HER2 amplification
 Yes 20 44.6 NS NS       25 22.3 NS NS      
 No (reference) 178 45.6         187 45.6        
  1. NS not significant, NA not applicable
  2. aExcluding trastuzumab-treated and stage IV patients
  3. bExcluding trastuzumab-treated patients
  4. cKaplan-Meier method
  5. dCox’s proportional hazards regression model